Base de dados : MEDLINE
Pesquisa : C04.588.945.440.770 [Categoria DeCS]
Referências encontradas : 106457 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 10646 ir para página                         

  1 / 106457 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29420981
[Au] Autor:Gaur S; Turkbey B
[Ad] Endereço:Molecular Imaging Program, National Cancer Institute, National Institutes of Health, 10 Center Drive, Building 10, Room B3B85, Bethesda, MD 20814, USA.
[Ti] Título:Prostate MR Imaging for Posttreatment Evaluation and Recurrence.
[So] Source:Radiol Clin North Am;56(2):263-275, 2018 Mar.
[Is] ISSN:1557-8275
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Prostate multiparametric MR imaging (mpMRI) plays an important role in local evaluation after treatment of prostate cancer. After radical prostatectomy, radiation therapy, and focal therapy, mpMRI can be used to visualize normal post-treatment changes and to diagnose locally recurrent disease. An understanding of the various treatments and expected changes is essential for complete and accurate post-treatment mpMRI interpretation.
[Mh] Termos MeSH primário: Imagem por Ressonância Magnética/métodos
Recidiva Local de Neoplasia/diagnóstico por imagem
Complicações Pós-Operatórias/diagnóstico por imagem
Próstata/diagnóstico por imagem
Neoplasias da Próstata/diagnóstico por imagem
Neoplasias da Próstata/cirurgia
[Mh] Termos MeSH secundário: Seres Humanos
Masculino
Recidiva Local de Neoplasia/patologia
Próstata/patologia
Neoplasias da Próstata/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180311
[Lr] Data última revisão:
180311
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180209
[St] Status:MEDLINE


  2 / 106457 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29376611
[Au] Autor:Epifanova MV; Chalyi ME; Gvasaliya BR; Eremin II; Pulin AA; Nadelyaeva II; Artemenko SA; Galitskaya DA; Repin AM
[Ad] Endereço:Research Institute for Uronephrology and Human Reproductive Health, Moscow, Russia.
[Ti] Título:[New approaches for recovery of erectile function in patients after radical prostatectomy].
[So] Source:Urologiia;(6):138-143, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:Prostate cancer (PCa) is one of the most common maligmancies and causes of death among men. Radical prostatectomy (RP) is optimal and recommended treatment modality for localized prostate cancer. More than half of all men undergoing surgery experience problems with erectile function and existing treatments do not provide a positive effect. Thus, there is a need for new approaches to the restoration of erectile function in patients after RP. One of these is the use of cell technologies, namely the stromal-vascular fraction and autologous platelet-rich plasma. This review examines the results of preclinical and clinical studies investigating the efficacy and safety of these treatment options in erectile dysfunction.
[Mh] Termos MeSH primário: Disfunção Erétil
Ereção Peniana
Complicações Pós-Operatórias/terapia
Prostatectomia/efeitos adversos
Neoplasias da Próstata/cirurgia
Recuperação de Função Fisiológica
[Mh] Termos MeSH secundário: Disfunção Erétil/etiologia
Disfunção Erétil/terapia
Seres Humanos
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE


  3 / 106457 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29376613
[Au] Autor:Akhvlediani ND; Shvarts PG; Kirichuk YV
[Ad] Endereço:I.M. Sechenov First MSMU of Minzdrav of Russia, Moscow, Russia.
[Ti] Título:[Erectile dysfunction after nerve-sparing radical prostatectomy].
[So] Source:Urologiia;(6):149-152, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:Nerve-sparing radical prostatectomy remains the optimal curative treatment of prostate cancer in patients who want to maintain erectile function. Since its development, there has been a gradual decline in its effectiveness concerning the prevention of ED, which was associated with the currently more objective assessment of erectile function at both the pre- and post-operative stage. There is a knowledge gap in the precise understanding of which specific neural structures should be preserved with the nerve-sparing technique. At the same time, there have been proposed effective methods for visualizing the elements of the preserved vascular-neural bundle and estimating the degree of nerve-sparing.
[Mh] Termos MeSH primário: Disfunção Erétil
Complicações Pós-Operatórias/prevenção & controle
Prostatectomia
Neoplasias da Próstata/cirurgia
[Mh] Termos MeSH secundário: Disfunção Erétil/etiologia
Disfunção Erétil/prevenção & controle
Seres Humanos
Masculino
Prostatectomia/efeitos adversos
Prostatectomia/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE


  4 / 106457 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29376605
[Au] Autor:Govorov AV; Vasilyev AO; Shiryaev AA; Sukhikh SO; Sidorenkov AV; Pushkarev AV; Tsiganov DI; Pushkar DY
[Ad] Endereço:Department of Urology, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia.
[Ti] Título:[Current methods of early diagnosis of prostate cancer].
[So] Source:Urologiia;(6):101-106, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:Prostate cancer is the most common cancer among men, except for lung cancer. Therefore, it is imperative to identify diagnostic methods for early detection of prostate cancer to determine patients from healthy populations, which helps guide a timely treatment at an initial stage of the disease. The article provides an in-depth review of the most current diagnostic biomarkers of prostate cancer, their role in clinical practice as a means of the early detection and screening for prostate cancer.
[Mh] Termos MeSH primário: Técnicas de Laboratório Clínico/métodos
Neoplasias da Próstata/diagnóstico
[Mh] Termos MeSH secundário: Técnicas de Laboratório Clínico/tendências
Seres Humanos
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE


  5 / 106457 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29028221
[Au] Autor:Verma V; Simone CB; Mishra MV
[Ad] Endereço:Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD.
[Ti] Título:Quality of Life and Patient-Reported Outcomes Following Proton Radiation Therapy: A Systematic Review.
[So] Source:J Natl Cancer Inst;110(4), 2018 Apr 01.
[Is] ISSN:1460-2105
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Background: As costs of cancer care rise, the importance of documenting value in oncology increases. Proton beam radiotherapy (PBT) has the potential to reduce toxicities in cancer patients, but is relatively expensive and unproven. Evaluating quality of life (QOL) and patient-reported outcomes (PROs) is essential to establishing PBT's "value" in oncologic therapy. The goal of this systematic review was to assess QOL and PROs in patients treated with PBT. Methods: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-guided systematic searches were conducted. The PubMed search engine was the primary data source, along with publications found from references of selected articles, and articles known to the authors published through 2017. Seventeen original investigations were found to have sufficient focus and relevance to be incorporated into the systematic review. Results: Studies of skull base (n = 1), brain (n = 1), head/neck (n = 1), lung (n = 1), breast (n = 2), prostate (n = 8), and pediatric (n = 3) malignancies treated with PBT that met eligibility criteria were included. QOL did not deteriorate during PBT for skull base and after PBT for brain tumors, respectively. PROs were higher for PBT than photon-based radiotherapy for both head/neck and lung cancer. Patient-reported breast cosmesis was appropriate after PBT and comparable to photon modalities. PBT in various settings of prostate cancer displayed an expected post-therapy decline; one study showed improved PROs (rectal urgency, bowel frequency) for PBT, and two others showed PROs/QOL comparable with other modalities. Pediatric studies demonstrated improvements in QOL during therapy, with additional increases thereafter. Conclusions: Based on limited data, PBT provides favorable QOL/PRO profiles for select brain, head/neck, lung, and pediatric cancers; measures for prostate and breast cancers were more modest. These results have implications for cost-effective cancer care and prudently designed QOL evaluation in ongoing trials, which are discussed. Future data could substantially change the conclusions of this review.
[Mh] Termos MeSH primário: Neoplasias/radioterapia
Medidas de Resultados Relatados pelo Paciente
Terapia com Prótons
Qualidade de Vida
[Mh] Termos MeSH secundário: Neoplasias Encefálicas/radioterapia
Neoplasias da Mama/radioterapia
Feminino
Neoplasias de Cabeça e Pescoço/radioterapia
Seres Humanos
Neoplasias Pulmonares/radioterapia
Masculino
Neoplasias da Próstata/radioterapia
Terapia com Prótons/efeitos adversos
Neoplasias da Base do Crânio/radioterapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171014
[St] Status:MEDLINE
[do] DOI:10.1093/jnci/djx208


  6 / 106457 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453693
[Au] Autor:Mahal BA; Chen YW; Muralidhar V; Mahal AR; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Yu JB; Feng FY; Kim SP; Beard CJ; Martin NE; Trinh QD; Nguyen PL
[Ad] Endereço:Harvard Radiation Oncology Program, Boston, USA.
[Ti] Título:Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.
[So] Source:Ann Oncol;28(5):1098-1104, 2017 05 01.
[Is] ISSN:1569-8041
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Background: In 2012, the United States Preventive Services Task Force (USPSTF) recommended against prostate-specific antigen (PSA) screening, despite evidence that Black men are at a higher risk of prostate cancer-specific mortality (PCSM). We evaluated whether Black men of potentially screening-eligible age (55-69 years) are at a disproportionally high risk of poor outcomes. Patients and methods: The SEER database was used to study 390 259 men diagnosed with prostate cancer in the United States between 2004 and 2011. Multivariable logistic regression modeled the association between Black race and stage of presentation, while Fine-Gray competing risks regression modeled the association between Black race and PCSM, both as a function of screening eligibility (age 55-69 years versus not). Results: Black men were more likely to present with metastatic disease (adjusted odds ratio [AOR] 1.65; 1.58-1.72; P < 0.001) and were at a higher risk of PCSM (adjusted hazard ratio [AHR] 1.36; 1.27-1.46; P < 0.001) compared to non-Black men. There were significant interactions between race and PSA-screening eligibility such that Black patients experienced more disproportionate rates of metastatic disease (AOR 1.76; 1.65-1.87 versus 1.55; 1.47-1.65; Pinteraction < 0.001) and PCSM (AHR 1.53; 1.37-1.70 versus 1.25; 1.14-1.37; Pinteraction = 0.01) in the potentially PSA-screening eligible group than in the group not eligible for screening. Conclusions: Racial disparities in prostate cancer outcome among Black men are significantly worse in PSA-screening eligible populations. These results raise the possibility that Black men could be disproportionately impacted by recommendations to end PSA screening in the United States and suggest that Black race should be included in the updated USPSTF PSA screening guidelines.
[Mh] Termos MeSH primário: Neoplasias da Próstata/diagnóstico
[Mh] Termos MeSH secundário: Afroamericanos
Idoso
Detecção Precoce de Câncer
Disparidades em Assistência à Saúde
Seres Humanos
Calicreínas/metabolismo
Masculino
Meia-Idade
Modelos de Riscos Proporcionais
Antígeno Prostático Específico/metabolismo
Neoplasias da Próstata/metabolismo
Neoplasias da Próstata/mortalidade
Neoplasias da Próstata/terapia
Fatores de Risco
Programa de SEER
Resultado do Tratamento
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
EC 3.4.21.- (Kallikreins); EC 3.4.21.- (kallikrein-related peptidase 3, human); EC 3.4.21.77 (Prostate-Specific Antigen)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1093/annonc/mdx041


  7 / 106457 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29292905
[Au] Autor:Henriksson R; Falkenius J; Norin S; Öhman D; Abrahamsson M; Lindquist M; Lööv SÅ
[Ad] Endereço:Onkologi & Patologi - Regionalt Cancercentrum STOCKHOLM, Sweden Onkologi & Patologi - Regionalt Cancercentrum STOCKHOLM, Sweden.
[Ti] Título:Register för nya läkemedel i cancervården ger värdefull hjälp - Visar en bra bild av hur läkemedlen används ­ patienten kan följas i den kliniska vardagen..
[So] Source:Lakartidningen;114, 2017 Nov 06.
[Is] ISSN:1652-7518
[Cp] País de publicação:Sweden
[La] Idioma:swe
[Ab] Resumo:Register for new drugs in cancer care provides a picture of how the drugs are used in the daily clinical practice Today, an increasing number of cancer drugs are approved before traditional well-controlled phase 3 studies have been conducted and in many registration studies there is no participation of Swedish departments. This article describes the general experience of a caregiver initiated systematic follow-up of new cancer drugs that shows the possibility of obtaining a picture of the drug's use in routine care. From the register "New Pharmaceuticals in Cancer care", registrations from Stockholm-Gotland region are reported. The structure of the registry can be used with advantage in other therapeutic areas than cancer and can be supplemented with data from national and regional registers as well as quality registers including patient experiences. The knowledge is important to many actors in health care and can contribute to an evidence based, patient-safe and equal healthcare in accordance with current guidelines.
[Mh] Termos MeSH primário: Antineoplásicos
Neoplasias/tratamento farmacológico
Sistema de Registros
[Mh] Termos MeSH secundário: Androstenos/uso terapêutico
Antineoplásicos/administração & dosagem
Antineoplásicos/uso terapêutico
Bevacizumab/uso terapêutico
Neoplasias da Mama/tratamento farmacológico
Neoplasias da Mama/mortalidade
Neoplasias Colorretais/tratamento farmacológico
Neoplasias Colorretais/mortalidade
Uso de Medicamentos
Seres Humanos
Ipilimumab/uso terapêutico
Masculino
Melanoma/tratamento farmacológico
Melanoma/mortalidade
Neoplasias/mortalidade
Cuidados Paliativos/métodos
Feniltioidantoína/análogos & derivados
Feniltioidantoína/uso terapêutico
Projetos Piloto
Neoplasias da Próstata/tratamento farmacológico
Neoplasias da Próstata/mortalidade
Rádio (Elemento)/uso terapêutico
Taxa de Sobrevida
Suécia/epidemiologia
Suspensão de Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androstenes); 0 (Antineoplastic Agents); 0 (Ipilimumab); 0 (MDV 3100); 0 (Radium-223); 2010-15-3 (Phenylthiohydantoin); 2S9ZZM9Q9V (Bevacizumab); G819A456D0 (abiraterone); W90AYD6R3Q (Radium)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180103
[St] Status:MEDLINE


  8 / 106457 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29220564
[Au] Autor:Benhaberou-Brun D
[Ti] Título:Cancer de la prostate. Les précautions liées à l'injection du dégarélix..
[So] Source:Perspect Infirm;14(3):52, 2017 May-Jun.
[Is] ISSN:1708-1890
[Cp] País de publicação:Canada
[La] Idioma:fre
[Mh] Termos MeSH primário: Oligopeptídeos/administração & dosagem
Neoplasias da Próstata/tratamento farmacológico
[Mh] Termos MeSH secundário: Seres Humanos
Injeções Subcutâneas/efeitos adversos
Injeções Subcutâneas/métodos
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Oligopeptides); 0 (acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:171209
[St] Status:MEDLINE


  9 / 106457 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463142
[Au] Autor:Spratt DE; Jagsi R
[Ad] Endereço:Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
[Ti] Título:Breast and Prostate Cancer: Lessons to Be Shared.
[So] Source:Int J Radiat Oncol Biol Phys;98(2):263-268, 2017 06 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Neoplasias da Mama/terapia
Terapia Combinada/métodos
Expectativa de Vida
Neoplasias da Próstata/terapia
Apoio à Pesquisa como Assunto
Terminologia como Assunto
[Mh] Termos MeSH secundário: Neoplasias da Mama/diagnóstico
Feminino
Seres Humanos
Masculino
Neoplasias da Próstata/diagnóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  10 / 106457 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29334632
[Au] Autor:MacLennan MS; Kok MGM; Soliman L; So A; Hurtado-Coll A; Chen DDY
[Ad] Endereço:University of British Columbia, Department of Chemistry, Vancouver, BC V6T 1Z1, Canada.
[Ti] Título:Capillary electrophoresis-mass spectrometry for targeted and untargeted analysis of the sub-5 kDa urine metabolome of patients with prostate or bladder cancer: A feasibility study.
[So] Source:J Chromatogr B Analyt Technol Biomed Life Sci;1074-1075:79-85, 2018 Feb 01.
[Is] ISSN:1873-376X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Targeted and untargeted analyses of the sub-5 kDa urine metabolome of genitourinary cancer patients (prostate and/or bladder) were performed without chemical derivatization using capillary electrophoresis-electrospray ionization-mass spectrometry (CE-ESI-MS). For targeted analysis, endogenous levels of sarcosine and 5 other amino acid metabolites implicated in the progression of prostate cancer were quantified in four patients and in a pooled urine sample from healthy volunteers. An untargeted analysis (m/z 50 to 850) of patient urine was performed using the same CE-ESI-MS system identifying over 400 distinct molecular features per patient. All patient urine samples were collected at prostatectomy/cystectomy via catheter. Patient urine samples were filtered by centrifugation, with endogenous sarcosine enriched by solid-phase extraction, and the processed samples loaded onto CE-ESI-MS for analysis. Diagnostic information, digital pathological slides, and tissue samples were collected and stored in a comprehensive biobanking database. The introduction of urine sample collection into the surgery workflow was facile and is a promising strategy for addressing the translational research challenge of moving smoothly from "chromatogram to nomogram".
[Mh] Termos MeSH primário: Biomarcadores Tumorais
Eletroforese Capilar/métodos
Metaboloma
Neoplasias da Próstata
Neoplasias da Bexiga Urinária
[Mh] Termos MeSH secundário: Adulto
Biomarcadores Tumorais/metabolismo
Biomarcadores Tumorais/urina
Estudos de Viabilidade
Seres Humanos
Masculino
Metabolômica/métodos
Neoplasias da Próstata/metabolismo
Neoplasias da Próstata/urina
Reprodutibilidade dos Testes
Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por Matriz/métodos
Neoplasias da Bexiga Urinária/metabolismo
Neoplasias da Bexiga Urinária/urina
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180116
[St] Status:MEDLINE



página 1 de 10646 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde